Another positive is we have made a discovery that will allow us to significantly speed up the downstream clinical trials which we probably wouldn’t have found if the engineering batch had been manufactured more efficiently.
Hi@Davisite , I assume that this discovery will be talked about in detail in the new strategy ?
I am a bit confused by this.
Did you mean that you wouldn't have found this discovery if the engineering batch had been manufactured LESS efficiently , instead of more ?
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-223
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.005(0.34%) |
Mkt cap ! $249.7M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.50 | $1.46 | $129.2K | 87.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7418 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 38353 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |